When close to half the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or “P/S”) below 0.9x, you may consider Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) as a stock to avoid entirely with its 42.6x P/S ratio. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s so lofty. Check out our latest analysis for Mezzion PharmaLtd KOSDAQ:A140410 Price to Sales Ratio vs Industry September 27th 2024 How Mezzion PharmaLtd…
Read More…
Mezzion Pharma Co.,Ltd.’s (KOSDAQ:140410) Shareholders Might Be Looking For Exit
